NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.15 (-0.19%) GOLD FUTURES
2,434.20 -4.30 (-0.18%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,854.37 +2,601.07 (+4.98%)
NRx Pharmaceuticals, Inc. (NRXP)
After hours:
| Previous close | 3.5400 |
| Open | 3.5300 |
| Bid | 4.0400 x 200 |
| Ask | 4.1100 x 200 |
| Day's range | 3.5014 - 4.2100 |
| 52-week range | 1.9000 - 12.0000 |
| Volume | |
| Avg. volume | 453,393 |
| Market cap | 43.444M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 0.78 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
- PR Newswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.
- PR Newswire
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2024 financial results after the market closes on Tuesday, May 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.
